Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1498TiP - A multi-center, randomized, open-label, phase III study of sintilimab + ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-106)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Gastric Cancer

Presenters

Ruihua Xu

Citation

Annals of Oncology (2020) 31 (suppl_4): S841-S873. 10.1016/annonc/annonc284

Authors

R. Xu1, Z. Li2, Z. Ma2, Y. Liu2, Y. Wang3, H. Zhou2, L. Yang4, H. Li4

Author affiliations

  • 1 Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Medical Oncology, Innovent Biologics, Inc., 200050 - Shanghai/CN
  • 3 Oncology, Innovent Biologics, Inc., 100021 - Beijing/CN
  • 4 Medical Oncology, Eli Lilly and Company, 200041 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1498TiP

Background

Systemic chemotherapy is currently still the only option for unresectable locally advanced or metastatic G/GEJ, and the prognosis for these patients is poor with median overall survival (OS) only around 1 year. Pre-clinical studies suggest that anti-VEGF receptor 2 (VEGFR-2) antibody can reprogram the tumor microenvironment away from immunosuppression. The synergistic anti-tumor activities by blockade of PD-1 and VEGFR-2 were also observed in clinical settings. On this basis, ORIENT-106 study is conducted to investigate the efficacy and safety of sintilimab (an IgG4 PD-1 antagonist) plus ramucirumab (an IgG1 VEGFR-2 antagonist) in advanced G/GEJ adenocarcinoma.

Trial design

Patients with unresectable locally advanced or metastatic G/GEJ adenocarcinoma, without prior therapy for advanced disease, who have PD-L1 expression CPS ≥ 10 and are HER2 negative, will be enrolled and randomized in a 1:1 ratio to receive either sintilimab plus ramucirumab every 3 weeks or chemotherapy by investigator’s choice of FP (5-FU plus cisplatin) or CapeOx (Capecitabine plus oxaliplatin) every 3 weeks. Combination chemotherapy is given up to 6 cycles, followed by 5-FU or capecitabine maintenance monotherapy. In the immunotherapy group, treatment beyond progressive disease is allowed. Stratification factors include ECOG performance status (0 or 1), primary tumor location (gastric or GEJ) and measurable lesion (with or without). Primary endpoint is OS. Secondary endpoints include progression free survival, objective response rate, disease control rate, duration of response, assessed by investigator based on RECIST v1.1 and iRECIST criteria, safety profile and PK characteristics. Planned enrollment is approximately 540 patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Innovent Biologics, Inc. and Eli Lilly and Company.

Funding

Innovent Biologics, Inc. and Eli Lilly and Company.

Disclosure

Z. Li, Z. Ma, Y. Liu, Y. Wang, H. Zhou: Full/Part-time employment: Innovent Biologics, Inc. L. Yang, H. Li: Full/Part-time employment: Eli Lilly and Company. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.